



Serial No. 10/634,682

Amendments to the Claims:

1. (Currently Amended) A pyrimidinyl compound
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]
amino]benzonitrile, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically
isomeric form thereof, said compound having the following structure:



2. (Currently Amended) A pyrimidinyl compound according to claim 1 wherein the pyrimidinyl compound is 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile, said compound having the following structure:



3. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active an effective amount of a pyrimidinyl compound according to claims 1 or 2 any of claims 1 or 2 or any of claims 23 to 33.

4. (Currently Amended) A combination comprising a pyrimidinyl compound according to claims 1 or 2 any of claims 1 or 2 or any of claims 23 to 33 and an antiretroviral compound, wherein said antiretroviral compound comprises at least one of a nucleoside reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a TIBO compound, an α -APA compound, a TAT-inhibitor, a protease inhibitor, an immunomodulating agent, and mixtures thereof.

5. (Original) A combination according to claim 4, wherein said nucleoside reverse transcriptase inhibitor comprises at least one of zidovudine (3'-azido-3'-deoxythymidine,

Serial No. 10/634,682

AZT), didanosine (dideoxy inosine; ddI), zalcitabine (dideoxycytidine, ddC), lamivudine (3'-thia-2'-3'-dideoxycytidine, 3TC), and mixtures thereof.

6. (Currently Amended) A combination according to claim 4, wherein said non-nucleoside reverse transcriptase inhibitors comprises at least one of suramine, pentamidine, thymopentin, castanospermine, efavirenz, dextran (dextran sulfate), fosfarnet-sodium (trisodium phosphono formate), nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one), tacrine (tetrahydroaminoacridine), and mixtures thereof.

7. (Original) A combination according to claim 4, wherein said TIBO compound comprises (S)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo-[4,5,1-jk][1,4]benzodiazepine-2(1*H*)-thione.

8. (Original) A combination according to claim 4, wherein said α-APA compound comprises α-[(2-nitro-phenyl)amino]-2,6-dichlorobenzene-acetamide.

9. (Original) A combination according to claim 4, wherein said protease inhibitor comprises at least one of indinavir, ritonavir, saquinavir, ABT-378, and mixtures thereof.

10. (Original) A combination according to claim 4, comprising at least one of RO-5-3335, levamisole, and mixtures thereof.

11. (Original) A combination according to claim 5, further comprising a pharmaceutically acceptable carrier.

12. (Original) A combination according to claim 6, further comprising a pharmaceutically acceptable carrier.

13. (Original) A combination according to claim 7, further comprising a pharmaceutically acceptable carrier.

14. (Original) A combination according to claim 8, further comprising a pharmaceutically acceptable carrier.

Serial No. 10/634,682


15. (Original) A combination according to claim 9, further comprising a pharmaceutically acceptable carrier.

16. (Original) A combination according to claim 10, further comprising a pharmaceutically acceptable carrier.

17. (Original) A combination according to claim 4 wherein said pyrimidinyl compound and said antiretroviral compound are combined in a single preparation.

18. (Original) A combination according to claim 17, further comprising a pharmaceutically acceptable carrier.

19. (Currently Amended) A process for preparing a compound as claimed in ~~claim 2, either of claims 2 or 27,~~ comprising reacting a compound of formula



with NH₃ in the presence of a reaction inert solvent.

20. (Original) A process according to claim 19, wherein said reacting is performed in the presence of a base.

21. (Currently Amended) A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject ~~a therapeutically effective amount of a compound according to claims 1 or 2, any of claims 1 or 2 or of claims 23 to 27.~~

22. (Original) A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a therapeutically effective amount of a combination according to claim 4.

23. (New) A pyrimidinyl compound as claimed in claim 1, wherein the compound is an addition salt of 4-[(4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl)amino]benzonitrile.

Serial No. 10/634,682

24. (New) A pyrimidinyl compound as claimed in claim 23, wherein the compound is the hydrochloride salt of 4-[(4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile.
25. (New) A pyrimidinyl compound as claimed in claim 1, wherein the compound is a quaternary amine of 4-[(4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile.
26. (New) An isolated compound as claimed in any of claims 1 or 2 or any of claims 23 to 25.
27. (New) A substantially pure compound as claimed in any of claims 1 or 2 or any of claims 23 to 25.
28. (New) A pharmaceutical composition as claimed in claim 3, wherein the pharmaceutical composition is a tablet.
29. (New) A pharmaceutical composition as claimed in claim 3, wherein the effective amount is between 1 to 1000 mg of active ingredient per unit dosage form.
30. (New) A pharmaceutical composition as claimed in claim 29, wherein the effective amount is between 5 and 200 mg of active ingredient per unit dosage form.
31. (New) A tablet as claimed in claim 28, wherein the effective amount is between 1 to 1000 mg of active ingredient.
32. (New) A tablet as claimed in claim 31, wherein the effective amount is between 5 to 200 mg of active ingredient.
33. (New) A method of treating a subject suffering from HIV-1 (Human Immunodeficiency Virus) infection comprising administering to the subject an effective amount of a compound according to any of claims 1 or 2 or any of claims 23 to 27.

Serial No. 10/634,682

34. (New) A method of treating subjects suffering from HIV-1 (Human Immunodeficiency Virus) that have acquired resistance to art-known non-nucleoside reverse transcriptase inhibitors infection comprising administering to the subject an effective amount of a compound according to any of claims 1 or 2 or any of claims 23 to 27.

35. (New) A combination comprising a pyrimidinyl compound according to any of claims 1 or 2 or any of claims 23 to 27, and an antiretroviral compound, wherein said antiretroviral compound comprises at least one of a nucleoside reverse transcriptase inhibitor, a non-nucleoside reverse transcriptase inhibitor, a TIBO compound, an α-APA compound, a TAT-inhibitor, a protease inhibitor, an immunomodulating agent, and mixtures thereof as a combined preparation for simultaneous, separate or sequential use.

36. (New) A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a compound as claimed in any of claims 1 or 2 or any of claims 23 to 27 and another antiretroviral compound simultaneously, separately or sequentially.

37. (New) A method for inhibiting reverse transcriptase, comprising administering a compound as claimed in any of claims 1 or 2 or any of claims 23 to 27.

38. (New) The method of claim 43, carried out on mammalian cells.

39. (New) The method of claim 43, carried out on human cells.

40. (New) The method of claim 43, carried out on immune cells.

41. (New) The method of claim 43, carried out on human T-4 cells.